Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2022 - 2024)

Oramed Pharmaceuticals (ORMP) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $60000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other Non-Current Liabilities fell 1.64% year-over-year to $60000.0, compared with a TTM value of $60000.0 through Sep 2024, down 1.64%, and an annual FY2023 reading of $11000.0, down 81.97% over the prior year.
  • Other Non-Current Liabilities was $60000.0 for Q3 2024 at Oramed Pharmaceuticals, roughly flat from $60000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $99000.0 in Q1 2022 and bottomed at $11000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 3 years is $60090.9, with a median of $61000.0 recorded in 2022.
  • Peak annual rise in Other Non-Current Liabilities hit 10.0% in 2023, while the deepest fall reached 81.97% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $61000.0 in 2022, then tumbled by 81.97% to $11000.0 in 2023, then surged by 445.45% to $60000.0 in 2024.
  • Business Quant data shows Other Non-Current Liabilities for ORMP at $60000.0 in Q3 2024, $60000.0 in Q2 2024, and $63000.0 in Q1 2024.